Diagnostic Accuracy of MRI in Evaluating Response After Neoadjuvant Systemic Therapy in Operable Breast Cancer

被引:6
作者
Khazindar, Abdullah R. [1 ]
Hashem, Dalia Abdulmonem L. [2 ]
Abusanad, Atlal [3 ]
Bakhsh, Salwa, I [4 ]
Bin Mahfouz, Alya [5 ]
El-Diasty, Mohamed T. [5 ]
机构
[1] Univ Jeddah, Dept Radiol, Jeddah, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Diagnost Radiol, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia
[4] King Abdulaziz Univ, Dept Pathol, Jeddah, Saudi Arabia
[5] King Abdulaziz Univ Hosp, Dept Radiol, Jeddah, Saudi Arabia
关键词
breast cancer; magnetic resonance imaging; complete pathological response; accuracy; radiological complete response; neoadjuvant chemotherapy; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY;
D O I
10.7759/cureus.15516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Neoadjuvant chemotherapy (NAC) is an important step in the treatment of various types of breast cancer by downsizing the tumor to make it operable. Determining disease extent after NAC is essential for accurate surgical planning. MRI has been the gold standard for detecting tumors that are usually difficult to detect on ultrasound or mammography. However, the use of MRI after NAC is controversial. Therefore, we aimed to evaluate the diagnostic accuracy of post-NAC MRI in the detection of residual disease preoperatively and to investigate the factors associated with pathological complete response (pCR). Methodology This retrospective review study was approved by the institutional review board with waiving of the informed consent. A total of 90 charts between January 2016 and January 2019 were reviewed. Baseline lesion size was measured as the maximal diameter in a single dimension by pretreatment MRI. To assess the diagnostic accuracy of MRI in detecting residual disease, we used two different definitions of pCR in the breast. The first is the resolution of both invasive disease and ductal carcinoma in situ. The second is the resolution of the invasive disease only. As a secondary objective of the study, we assessed the association between different patients' characteristics and both MRI and pathologic response using univariate and multivariate analysis. Results A total of 52 women (mean age: 47.4 years; range: 28-74) with 56 breast masses were eligible for the study. Complete MRI response was noted in 22 ( 39%) masses. pCR was achieved in 14 (25%) and 25 (44.6%) masses using the first and second pCR definitions, respectively. The negative predictive value (NPV) and overall accuracy of MRI for detecting residual disease were 50% and 75%, respectively, using the first pCR definition. With the second pCR definition, NPV and accuracy were 77.3% and 76.8%, respectively. Positive axillary lymph nodes were the only significant factor associated with incomplete MRI and pathological responses. Conclusions MRI NPV for residual disease was higher with the second pCR definition; however, overall accuracy was not different. MRI accuracy in detecting residual disease after NAC is not adequate to replace pathological assessment.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Breast MRI for Evaluation of Response to Neoadjuvant Therapy
    Reig, Beatriu
    Lewin, Alana A.
    Du, Linda
    Heacock, Laura
    Toth, Hildegard K.
    Heller, Samantha L.
    Gao, Yiming
    Moy, Linda
    RADIOGRAPHICS, 2021, 41 (03) : 665 - 679
  • [32] The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis
    Li, Yan
    Zhou, Yidong
    Mao, Feng
    Lin, Yan
    Zhang, Xiaohui
    Shen, Songjie
    Sun, Qiang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [33] Mammographic density to predict response to neoadjuvant systemic breast cancer therapy
    Di Cosimo, S.
    Depretto, C.
    Miceli, R.
    Baili, P.
    Ljevar, S.
    Sant, M.
    Cappelletti, V
    Folli, S.
    Gennaro, M.
    De Braud, F. G.
    Bianchi, G.
    Vingiani, A.
    Pruneri, G.
    Marchiano, A.
    La Rocca, E.
    De Santis, M. C.
    Scaperrotta, G. P.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (04) : 775 - 781
  • [34] Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer after Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype
    Honda, Maya
    Kataoka, Masako
    Iima, Mami
    Ota, Rie
    Ohashi, Akane
    Kishimoto, Ayami Ohno
    Miyake, Kanae Kawai
    Nickel, Marcel Dominik
    Yamada, Yosuke
    Toi, Masakazu
    Nakamoto, Yuji
    TOMOGRAPHY, 2022, 8 (03) : 1522 - 1533
  • [35] The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis
    Cheng, Qingqing
    Huang, Jiaxi
    Liang, Jianye
    Ma, Mengjie
    Ye, Kunlin
    Shi, Changzheng
    Luo, Liangping
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [36] Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer
    Simons, Janine M.
    van Nijnatten, Thiemo J. A.
    van der Pol, Carmen C.
    Luiten, Ernest J. T.
    Koppert, Linetta B.
    Smidt, Marjolein L.
    ANNALS OF SURGERY, 2019, 269 (03) : 432 - 442
  • [37] MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer
    Sener, Stephen F.
    Sargent, Rachel E.
    Lee, Connie
    Manchandia, Tejas
    Le-Tran, Vivian
    Olimpiadi, Yuliya
    Zaremba, Nicole
    Alabd, Andrew
    Nelson, Maria
    Lang, Julie E.
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (06) : 903 - 910
  • [38] Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
    Onishi, Natsuko
    Li, Wen
    Gibbs, Jessica
    Wilmes, Lisa J.
    Nguyen, Alex
    Jones, Ella F.
    Arasu, Vignesh
    Kornak, John
    Joe, Bonnie N.
    Esserman, Laura J.
    Newitt, David C.
    Hylton, Nola M.
    TOMOGRAPHY, 2020, 6 (02) : 77 - 85
  • [39] Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer:: the role of clinical response
    Pierga, JY
    Mouret, E
    Laurence, V
    Diéras, V
    Savigioni, A
    Beuzeboc, P
    Dorval, T
    Palangié, T
    Jouve, M
    Pouillart, P
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (08) : 1089 - 1096
  • [40] Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer
    Rauch, Gaiane M.
    Adrada, Beatriz Elena
    Kuerer, Henry Mark
    van la Parra, Raquel F. D.
    Leung, Jessica W. T.
    Yang, Wei Tse
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2017, 208 (02) : 290 - 299